Biolytica aims to become the leading data platform for preventive healthcare and longevity. The start-up that is already generating 6-figure turnover has now secured funding totalling CHF 5.25m from the Maximon Longevity Co-Investment Fund.
Biolytica’s focus is its Biolytica NEXUS health data platform, a AI-driven analytics platform that aggregates, visualizes and analyzes data from genomics, blood and epigenetic biomarkers, as well as microbiome biomarkers, wearable devices, lifestyle data and more. This enables Biolytica to provide solutions for healthcare professionals such as preventive medicine institutions, longevity centers, personalized wellness clinics but also insurance companies and others to create hyper-personalized client health journeys, based on the latest science.
Maximon's backing underscores the growing interest in and demand for longevity solutions backed by solid scientific research. As people around the world seek ways to extend their healthy lifespan, and the move from “sick-care” to “health-care” trends, Biolytica is poised to become a leader in this rapidly evolving field.
Successful launch of the platform
Developing the platform in “stealth mode” since Biolytica’s incorporation in October 2021 (with the conceptual origins going back to 2016), Biolytica has launched its platform to healthcare institutions in early 2023 and is already generating 6-figure turnover, expecting to hit mid-7 figures by the end of the year.
Biolytica currently has a team of more than 40 global experts in health data, analytics, software development, bioinformatics and AI, as well as a team of clinical experts from around the globe – and support from 10 prolific scientific and medical advisors.
B2C offering
In addition to their B2B platform services, they also offer B2C concierge health optimization and longevity programs, provided by their internal team of longevity experts and backed by their Biolytica NEXUS platform. These exclusive “AIME” programs offer personalized guidance and support for clients seeking to optimize their health and extend their lifespan with a strictly data- and science-driven approach.
"The team at Biolytica is at the forefront of hyper-personalized health, data analytics and lifespan extension," says Joerg Rieker, Founding Partner at Maximon and Board Member of Biolytica. "We are confident that their unique approach to science-based, data-driven and AI supported healthcare will have a transformative impact not only on the longevity industry, but on healthcare and prevention in general."
"We are thrilled to have Maximon's support in our mission to revolutionize how we think about health and prevention in particular," says Rob Konrad Maciejweski, CEO and Founder of Biolytica.
(Press release / SK)
Please login or sign up to comment.
Commenting guidelines